{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T23:10:51Z","timestamp":1791587451477,"version":"4.3.4"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T00:00:00Z","timestamp":1633651200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T00:00:00Z","timestamp":1633651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1038\/s41440-021-00771-6","type":"journal-article","created":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T12:10:53Z","timestamp":1633695053000},"page":"53-60","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Differential impact of antihypertensive drugs on cardiovascular remodeling: a review of findings and perspectives for HFpEF prevention"],"prefix":"10.1038","volume":"45","author":[{"given":"Takeshi","family":"Takami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Hoshide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuomi","family":"Kario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,8]]},"reference":[{"key":"771_CR1","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1161\/CIRCULATIONAHA.118.035858","volume":"138","author":"S Yasuda","year":"2018","unstructured":"Yasuda S, Miyamoto Y, Ogawa H. Current status of cardiovascular medicine in the aging society of Japan. Circulation. 2018;138:965\u20137.","journal-title":"Circulation"},{"key":"771_CR2","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1253\/circj.72.489","volume":"72","author":"Y Okura","year":"2008","unstructured":"Okura Y, Ramadan MM, Ohno Y, Mitsuma W, Tanaka K, Ito M, et al. Impending epidemic: future projection of heart failure in Japan to the year 2055. Circ J. 2008;72:489\u201391.","journal-title":"Circ J"},{"key":"771_CR3","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","volume":"136","author":"CW Yancy","year":"2017","unstructured":"Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, et al. ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 2017;136:e137\u2013e161. 2017","journal-title":"Circulation"},{"key":"771_CR4","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1253\/circj.CJ-19-0342","volume":"83","author":"H Tsutsui","year":"2019","unstructured":"Tsutsui H, Isobe M, Ito H, Ito H, Okumura K, Ono M, et al. JCS 2017\/JHFS 2017 Guideline on diagnosis and treatment of acute and chronic heart failure- digest version. Circ J. 2019;83:2084\u2013184.","journal-title":"Circ J."},{"key":"771_CR5","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129\u20132200.","journal-title":"Eur Heart J"},{"key":"771_CR6","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","volume":"362","author":"S Yusuf","year":"2003","unstructured":"Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003;362:777\u201381.","journal-title":"Lancet"},{"key":"771_CR7","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","volume":"381","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP. et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381:1609\u201320.","journal-title":"N Engl J Med"},{"key":"771_CR8","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S2213-8587(17)30087-6","volume":"5","author":"JP Seferovic","year":"2017","unstructured":"Seferovic JP, Claggett B, Seidelmann SB, Seely EW, Packer M, Zile MR, et al. Effect of sacubitril\/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 2017;5:333\u201340.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"771_CR9","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1161\/HYPERTENSIONAHA.114.03617","volume":"65","author":"Z Sun","year":"2015","unstructured":"Sun Z. Aging, arterial stiffness, and hypertension. Hypertension 2015;65:252\u20136.","journal-title":"Hypertension"},{"key":"771_CR10","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s12872-017-0642-y","volume":"17","author":"T Li","year":"2017","unstructured":"Li T, Chen S, Guo X, Yang J, Sun Y. Impact of hypertension with or without diabetes on left ventricular remodeling in rural Chinese population: a cross-sectional study. BMC Cardiovasc Disord. 2017;17:206.","journal-title":"BMC Cardiovasc Disord"},{"key":"771_CR11","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1152\/physiolgenomics.00122.2016","volume":"49","author":"MS Newman","year":"2017","unstructured":"Newman MS, Nguyen T, Watson MJ, Hull RW, Yu HG. Transcriptome profiling reveals novel BMI- and sex-specific gene expression signatures for human cardiac hypertrophy. Physiol Genomics. 2017;49:355\u201367.","journal-title":"Physiol Genomics"},{"key":"771_CR12","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0895-7061(03)01004-5","volume":"16","author":"A Ichihara","year":"2003","unstructured":"Ichihara A, Hayashi M, Koura Y, Tada Y, Hirota N, Saruta T. Long-term effects of intensive blood pressure lowering on arterial wall stiffness in hypertensive patients. Am J Hypertens. 2003;16:959\u201365.","journal-title":"Am J Hypertens"},{"key":"771_CR13","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1161\/CIRCULATIONAHA.117.028441","volume":"136","author":"EZ Soliman","year":"2017","unstructured":"Soliman EZ, Ambrosius WT, Cushman WC, Zhang ZM, Bates JT, Neyra JA, et al. Effect of intensive blood pressure lowering on left ventricular hypertrophy in patients with hypertension: SPRINT (Systolic Blood Pressure Intervention Trial). Circulation 2017;136:440\u201350.","journal-title":"Circulation"},{"key":"771_CR14","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","volume":"373","author":"JT Wright Jr","year":"2015","unstructured":"SPRINT Research Group, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103\u201316.","journal-title":"N Engl J Med"},{"key":"771_CR15","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1161\/HYPERTENSIONAHA.118.11554","volume":"72","author":"A Tanaka","year":"2018","unstructured":"Tanaka A, Tomiyama H, Maruhashi T, Matsuzawa Y, Miyoshi T, Kabutoya T, et al. Physiological diagnosis criteria for vascular failure committee. Physiological diagnostic criteria for vascular failure. Hypertension 2018;72:1060\u201371.","journal-title":"Hypertension"},{"key":"771_CR16","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1111\/jch.13966","volume":"22","author":"A Kollias","year":"2020","unstructured":"Kollias A, Kyriakoulis KG, Gravvani A, Anagnostopoulos I, Stergiou GS. Automated pulse wave velocity assessment using a professional oscillometric office blood pressure monitor. J Clin Hypertens (Greenwich). 2020;22:1817\u201323.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"771_CR17","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41440-019-0364-x","volume":"43","author":"A Nakagomi","year":"2020","unstructured":"Nakagomi A, Imazeki F, Nishimura M, Sawabe Y, Matsushita K, Murata A, et al. Central blood pressure and pulse wave velocity in young and middle-aged Japanese adults with isolated systolic hypertension. Hypertens Res. 2020;43:207\u201312.","journal-title":"Hypertens Res"},{"key":"771_CR18","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41440-020-00546-5","volume":"44","author":"A Tanaka","year":"2021","unstructured":"Tanaka A, Toyoda S, Node K. Vascular functional tests and preemptive medicine. Hypertens Res. 2021;44:117\u20139.","journal-title":"Hypertens Res"},{"key":"771_CR19","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41440-020-0523-0","volume":"44","author":"M Fujii","year":"2021","unstructured":"Fujii M, Tomiyama H, Nakano H, Iwasaki Y, Matsumoto C, Shiina K, et al. Differences in longitudinal associations of cardiovascular risk factors with arterial stiffness and pressure wave reflection in middle-aged Japanese men. Hypertens Res. 2021;44:98\u2013106.","journal-title":"Hypertens Res"},{"key":"771_CR20","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1161\/HYPERTENSIONAHA.115.06066","volume":"67","author":"A Kollias","year":"2016","unstructured":"Kollias A, Lagou S, Zeniodi ME, Boubouchairopoulou N, Stergiou GS. Association of central versus brachial blood pressure with target-organ damage: systematic review and meta-analysis. Hypertension 2016;67:183\u201390.","journal-title":"Hypertension"},{"key":"771_CR21","first-page":"894","volume":"120","author":"J Bulas","year":"2019","unstructured":"Bulas J, Potocarova M, Kupcova V, Gaspar L, Wimmer G, Murin J. Central systolic blood pressure increases with aortic stiffness. Bratisl Lek Listy. 2019;120:894\u20138.","journal-title":"Bratisl Lek Listy"},{"key":"771_CR22","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1080\/08037051.2017.1394791","volume":"27","author":"A Jekell","year":"2018","unstructured":"Jekell A, Kahan T. The usefulness of a single arm cuff oscillometric method (Arteriograph) to assess changes in central aortic blood pressure and arterial stiffness by antihypertensive treatment: results from the Doxazosin-Ramipril Study. Blood Press. 2018;27:88\u201398.","journal-title":"Blood Press"},{"key":"771_CR23","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1291\/hypres.26.609","volume":"26","author":"T Takami","year":"2003","unstructured":"Takami T, Shigemasa M. Efficacy of various antihypertensive agents as evaluated by indices of vascular stiffness in elderly hypertensive patients. Hypertens Res. 2003;26:609\u201314.","journal-title":"Hypertens Res"},{"key":"771_CR24","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/hr.2009.156","volume":"32","author":"T Takami","year":"2009","unstructured":"Takami T. Evaluation of arterial stiffness in morning hypertension under high-dose valsartan compared to valsartan plus low-dose diuretic. Hypertens Res. 2009;32:1086\u201390.","journal-title":"Hypertens Res"},{"key":"771_CR25","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/ajh.2011.109","volume":"24","author":"H Tomiyama","year":"2011","unstructured":"Tomiyama H, Yoshida M, Yamada J, Matsumoto C, Odaira M, Shiina K, et al. Arterial-cardiac destiffening following long-term antihypertensive treatment. Am J Hypertens. 2011;24:1080\u20136.","journal-title":"Am J Hypertens"},{"key":"771_CR26","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.amjhyper.2005.08.007","volume":"19","author":"Z Dhakam","year":"2006","unstructured":"Dhakam Z, McEniery CM, Yasmin, Cockcroft JR, Brown MJ, Wilkinson IB. Atenolol and eprosartan: differential effects on central blood pressure and aortic pulse wave velocity. Am J Hypertens. 2006;19:214\u20139.","journal-title":"Am J Hypertens"},{"key":"771_CR27","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1038\/s41440-019-0284-9","volume":"42","author":"S Umemura","year":"2019","unstructured":"Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). Hypertens Res. 2019;42:1235\u2013481.","journal-title":"Hypertens Res"},{"key":"771_CR28","first-page":"e13","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, et al. 2017ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018;71:e13\u2013e115.","journal-title":"Hypertension"},{"key":"771_CR29","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC\/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021\u2013104.","journal-title":"Eur Heart J"},{"key":"771_CR30","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1161\/HYPERTENSIONAHA.109.131466","volume":"54","author":"Y Matsui","year":"2009","unstructured":"Matsui Y, Eguchi K, O\u2019Rourke MF, Ishikawa J, Miyashita H, Shimada K, et al. Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients. Hypertension. 2009;54:716\u201323.","journal-title":"Hypertension"},{"key":"771_CR31","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2147\/VHRM.S21991","volume":"7","author":"T Takami","year":"2011","unstructured":"Takami T, Saito Y. Effects of Azelnidipine plus OlmesaRTAn versus amlodipine plus olmesartan on central blood pressure and left ventricular mass index: the AORTA study. Vasc Health Risk Manag. 2011;7:383\u201390.","journal-title":"Vasc Health Risk Manag"},{"key":"771_CR32","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/ajh.2012.64","volume":"25","author":"Y Matsui","year":"2012","unstructured":"Matsui Y, O\u2019Rourke MF, Ishikawa J, Shimada K, Kario K. Association of changes in ambulatory arterial stiffness index and pulse wave velocity during antihypertensive treatment: the J-CORE study. Am J Hypertens. 2012;25:862\u20138.","journal-title":"Am J Hypertens"},{"key":"771_CR33","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2147\/DDDT.S42338","volume":"7","author":"T Takami","year":"2013","unstructured":"Takami T, Saito Y. Azelnidipine plus olmesartan versus amlodipine plus olmesartan on arterial stiffness and cardiac function in hypertensive patients: a randomized trial. Drug Des Devel Ther. 2013;7:175\u201383.","journal-title":"Drug Des Devel Ther"},{"key":"771_CR34","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1161\/HYPERTENSIONAHA.116.08556","volume":"69","author":"B Williams","year":"2017","unstructured":"Williams B, Cockcroft JR, Kario K, Zappe DH, Brunel PC, Wang Q, et al. Effects of sacubitril\/valsartan versus olmesartan on central hemodynamics in the elderly with systolic hypertension: the PARAMETER Study. Hypertension 2017;69:411\u201320.","journal-title":"Hypertension"},{"key":"771_CR35","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1093\/eurheartj\/ehx525","volume":"38","author":"RE Schmieder","year":"2017","unstructured":"Schmieder RE, Wagner F, Mayr M, Delles C, Ott C, Keicher C, et al. The effect of sacubitril\/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study. Eur Heart J. 2017;38:3308\u201317.","journal-title":"Eur Heart J"},{"key":"771_CR36","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1093\/ajh\/hpz050","volume":"32","author":"EJ Cho","year":"2019","unstructured":"Cho EJ, Lee HY, Sung KC, Park S, Sohn IS, Park CG, et al. Comparison of 24-hour ambulatory central blood pressure reduction efficacy between fixed amlodipine or up-titrated hydrochlorothiazide plus losartan: the K-Central Study. Am J Hypertens. 2019;32:992\u20131002.","journal-title":"Am J Hypertens"},{"key":"771_CR37","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1161\/01.RES.0000256155.31133.49","volume":"100","author":"K Hayashi","year":"2007","unstructured":"Hayashi K, Wakino S, Sugano N, Ozawa Y, Homma K, Saruta T. Ca2+ channel subtypes and pharmacology in the kidney. Circ Res. 2007;100:342\u201353.","journal-title":"Circ Res"},{"key":"771_CR38","first-page":"FC13","volume":"9","author":"RM Pathapati","year":"2015","unstructured":"Pathapati RM, Rajashekar ST, Buchineni M, Meriga RK, Reddy CB, Kumar KP. An open label parallel group study to assess the effects of amlodipine and cilnidipine on pulse wave velocity and augmentation pressures in mild to moderate essential hypertensive patients. J Clin Diagn Res. 2015;9:FC13\u20136.","journal-title":"J Clin Diagn Res"},{"key":"771_CR39","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1097\/HJH.0000000000000270","volume":"32","author":"J Inomata","year":"2014","unstructured":"Inomata J, Murai H, Kaneko S, Hamaoka T, Ikeda T, Kobayashi D, et al. Differential effects of azelnidipine and amlodipine on sympathetic nerve activity in patients with primary hypertension. J Hypertens. 2014;32:1898\u2013904.","journal-title":"J Hypertens"},{"key":"771_CR40","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/hr.2011.143","volume":"35","author":"H Shimizu","year":"2012","unstructured":"Shimizu H, Nakagami H, Yasumasa N, Mariana OK, Kyutoku M, Koriyama H, et al. Cilnidipine, but not amlodipine, ameliorates osteoporosis in ovariectomized hypertensive rats through inhibition of the N-type calcium channel. Hypertens Res. 2012;35:77\u201381.","journal-title":"Hypertens Res"},{"key":"771_CR41","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3109\/08037051.2012.694200","volume":"21","author":"C Ogura","year":"2012","unstructured":"Ogura C, Ono K, Miyamoto S, Ikai A, Mitani S, Sugimoto N, et al. L\/T-type and L\/N-type calcium-channel blockers attenuate cardiac sympathetic nerve activity in patients with hypertension. Blood Press. 2012;21:367\u201371.","journal-title":"Blood Press"},{"key":"771_CR42","doi-asserted-by":"publisher","unstructured":"Yamamoto K, Rakugi H. Angiotensin receptor neprilysin inhibitors. Comprehensive review and implication in hypertension treatment. Hypertens Res. 2021. https:\/\/doi.org\/10.1038\/s41440-021-00706-1. e-pub ahead of print 21 Juy 2021.","DOI":"10.1038\/s41440-021-00706-1"},{"key":"771_CR43","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1177\/0091270009343932","volume":"50","author":"J Gu","year":"2010","unstructured":"Gu J, Noe A, Chandra P, Al-Fayoumi S, Ligueros-Saylan M, Sarangapani R, et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharm. 2010;50:401\u201314.","journal-title":"J Clin Pharm"},{"key":"771_CR44","doi-asserted-by":"publisher","unstructured":"Kario K, Williams B. Nocturnal hypertension and heart failure mechanisms, evidence, and new treatments hypertension. 2021; 78. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.121.17440.","DOI":"10.1161\/HYPERTENSIONAHA.121.17440"},{"key":"771_CR45","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1161\/CIRCULATIONAHA.115.018622","volume":"133","author":"SA Hubers","year":"2016","unstructured":"Hubers SA, Brown NJ. Combined angiotensin receptor antagonism and neprilysin inhibition. Circulation 2016;133:1115\u201324.","journal-title":"Circulation"},{"key":"771_CR46","doi-asserted-by":"crossref","first-page":"e112986","DOI":"10.1371\/journal.pone.0112986","volume":"9","author":"S Pan","year":"2014","unstructured":"Pan S, Chen HH, Correia C, Dai H, Witt TA, Kleppe LS, et al. Cell surface protein disulfide isomerase regulates natriuretic peptide generation of cyclic guanosine monophosphate. PLoS ONE. 2014;9:e112986.","journal-title":"PLoS ONE"},{"key":"771_CR47","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1161\/CIRCULATIONAHA.106.652842","volume":"115","author":"D Levy","year":"2007","unstructured":"Levy D, Hwang SJ, Kayalar A, Benjamin EJ, Vasan RS, Parise H, et al. Associations of plasma natriuretic peptide, adrenomedullin, and homocysteine levels with alterations in arterial stiffness: the Framingham Heart Study. Circulation 2007;115:3079\u201385.","journal-title":"Circulation"},{"key":"771_CR48","doi-asserted-by":"publisher","unstructured":"Hoshide S, Kanegae H, Kario K Nighttime home blood pressure as a mediator of N-terminal pro-brain natriuretic peptide in cardiovascular events. Hypertens Res. 2021. https:\/\/doi.org\/10.1038\/s41440-021-00667-5.","DOI":"10.1038\/s41440-021-00667-5"},{"key":"771_CR49","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1161\/01.HYP.0000168053.34306.d4","volume":"46","author":"DA Kass","year":"2005","unstructured":"Kass DA. Ventricular arterial stiffening: integrating the pathophysiology. Hypertension. 2005;46:185\u201393.","journal-title":"Hypertension"},{"key":"771_CR50","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","volume":"359","author":"B Dahl\u00f6f","year":"2002","unstructured":"Dahl\u00f6f B, Devereux RB, Sverre EK, Julius S, Beevers G, de Faire U, et al. LIFE Study GroupCardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995\u20131003.","journal-title":"Lancet"},{"key":"771_CR51","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/HJH.0b013e32834103d4","volume":"29","author":"C Yoshida","year":"2011","unstructured":"Yoshida C, Goda A, Naito Y, Nakaboh A, Matsumoto M, Otsuka M, et al. Role of plasma aldosterone concentration in regression of left-ventricular mass following antihypertensive medication. J Hypertens. 2011;29:357\u201363.","journal-title":"J Hypertens"},{"key":"771_CR52","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1111\/jch.14047","volume":"22","author":"JS Chen","year":"2020","unstructured":"Chen JS, Pei Y, Li CE, Li YN, Wang QY, Yu J. Comparative efficacy of different types of antihypertensive drugs in reversing left ventricular hypertrophy as determined with echocardiography in hypertensive patients: a network meta-analysis of randomized controlled trials. J Clin Hypertens (Greenwich). 2020;22:2175\u201383.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"771_CR53","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1161\/CIRCULATIONAHA.106.668863","volume":"115","author":"J Burns","year":"2007","unstructured":"Burns J, Sivananthan MU, Ball SG, Mackintosh AF, Mary DA, Greenwood JP. Relationship between central sympathetic drive and magnetic resonance imaging-determined left ventricular mass in essential hypertension. Circulation 2007;115:1999\u20132005.","journal-title":"Circulation"},{"key":"771_CR54","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1081\/CEH-120025336","volume":"25","author":"T Takami","year":"2003","unstructured":"Takami T, Shigematsu M. Effects of calcium channel antagonists on left ventricular hypertrophy and diastolic function in patients with essential hypertension. Clin Exp Hypertens. 2003;25:525\u201335.","journal-title":"Clin Exp Hypertens"},{"key":"771_CR55","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1080\/10641963.2016.1267198","volume":"39","author":"S Kiuchi","year":"2017","unstructured":"Kiuchi S, Hisatake S, Kabuki T, Oka T, Dobashi S, Fujii T, et al. Azelnidipine is a useful medication for the treatment of heart failure preserved ejection fraction. Clin Exp Hypertens. 2017;39:350\u20134.","journal-title":"Clin Exp Hypertens"},{"key":"771_CR56","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1536\/ihj.17-024","volume":"59","author":"S Kiuchi","year":"2018","unstructured":"Kiuchi S, Hisatake S, Kabuki T, Oka T, Dobashi S, Fujii T, et al. Effect of switching from cilnidipine to azelnidipine on cardiac sympathetic nerve function in patients with heart failure preserved ejection fraction. Int Heart J. 2018;59:120\u20135.","journal-title":"Int Heart J"},{"key":"771_CR57","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1161\/01.CIR.0000029923.57048.61","volume":"106","author":"Y Li","year":"2002","unstructured":"Li Y, Kishimoto I, Saito Y, Harada M, Kuwahara K, Izumi T, et al. Guanylyl cyclase-A inhibits angiotensin II type 1A receptor-mediated cardiac remodeling, an endogenous protective mechanism in the heart. Circulation 2002;106:1722\u20138.","journal-title":"Circulation"},{"key":"771_CR58","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1001\/jama.288.10.1252","volume":"288","author":"RS Vasan","year":"2002","unstructured":"Vasan RS, Benjamin EJ, Larson MG, Leip EP, Wang TJ, Wilson PW. et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. J Am Med Assoc. 2002;288:1252\u20139.","journal-title":"J Am Med Assoc"},{"key":"771_CR59","doi-asserted-by":"publisher","unstructured":"Correale M, Mallardi A, Tricarico L, Mazzeo P, Ferraretti A, Diella C, et al. Remodelling is inversely proportional to left ventricular dimensions in a real-life population of patients with chronic heart failure after therapy with sacubitril\/valsartan. Acta Cardiol. 2021 Aug 6:1\u20136. https:\/\/doi.org\/10.1080\/00015385.2021.1950371.","DOI":"10.1080\/00015385.2021.1950371"},{"key":"771_CR60","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1253\/circj.CJ-16-0740","volume":"81","author":"T Komori","year":"2017","unstructured":"Komori T, Eguchi K, Saito T, Hoshide S, Kario K. C riser pattern is a novel predictor of adverse events in heart failure patients with preserved ejection fraction. Circ J. 2017;81:220\u20136.","journal-title":"Circ J"},{"key":"771_CR61","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/S0002-9149(01)01732-5","volume":"88","author":"H Tsutsui","year":"2001","unstructured":"Tsutsui H, Tsuchihashi M, Takeshita A. Mortality and readmission of hospitalized patients with congestive heart failure and preserved versus depressed systolic function. Am J Cardiol. 2001;88:530\u20133.","journal-title":"Am J Cardiol"},{"key":"771_CR62","doi-asserted-by":"crossref","first-page":"L77","DOI":"10.1093\/eurheartj\/suaa140","volume":"22","author":"E Gronda","year":"2020","unstructured":"Gronda E, Vanoli E, Iacoviello M. The PARAGON-HF trial: the sacubitril\/valsartan in heart failure with preserved ejection fraction. Eur Heart J Suppl. 2020;22:L77\u2013L81. Suppl L","journal-title":"Eur Heart J Suppl"},{"key":"771_CR63","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1161\/HYPERTENSIONAHA.120.16277","volume":"77","author":"K Suzuki","year":"2021","unstructured":"Suzuki K, Clagget B, Minamisawa M, Nochioka K, Mitchell GF, Anand IS, et al. Pulse pressure, prognosis, and influence of sacubitril\/valsartan in heart failure with preserved ejection fraction. Hypertension 2021;77:546\u201356.","journal-title":"Hypertension"},{"key":"771_CR64","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/2047487317747498","volume":"25","author":"C Mancusi","year":"2018","unstructured":"Mancusi C, Losi MA, Izzo R, Canciello G, Carlino MV, Albano G, et al. Higher pulse pressure and risk for cardiovascular events in patients with essential hypertension: the Campania Salute Network. Eur J Prev Cardiol. 2018;25:235\u201343.","journal-title":"Eur J Prev Cardiol"},{"key":"771_CR65","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1161\/01.CIR.96.6.1859","volume":"96","author":"T Uzu","year":"1997","unstructured":"Uzu T, Ishikawa K, Fujii T, Nakamura S, Inenaga T, Kimura G. Sodium restriction shifts circadian rhythm of blood pressure from nondipper to dipper in essential hypertension. Circulation 1997;96:1859\u201362.","journal-title":"Circulation"},{"key":"771_CR66","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1161\/CIRCULATIONAHA.120.049730","volume":"142","author":"K Kario","year":"2020","unstructured":"Kario K, Hoshide S, Mizuno H, Kabutoya T, Nishizawa M, Yoshida T, et al. Nighttime blood pressure phenotype and cardiovascular prognosis: practitioner-based nationwide JAMP study. Circulation 2020;142:1810\u201320.","journal-title":"Circulation"},{"key":"771_CR67","doi-asserted-by":"publisher","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, B\u00f6hm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021 Aug 27. https:\/\/doi.org\/10.1056\/NEJMoa2107038.","DOI":"10.1056\/NEJMoa2107038"},{"key":"771_CR68","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.119.042375","volume":"140","author":"S Verma","year":"2019","unstructured":"Verma S, Mazer CD, Yan AT, Mason T, Garg V, Teoh H, et al. Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART cardiolink-6 randomized clinical trial. Circulation 2019;140:1693\u2013702.","journal-title":"Circulation"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-021-00771-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-021-00771-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-021-00771-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T09:07:12Z","timestamp":1639386432000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-021-00771-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,8]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["771"],"URL":"https:\/\/doi.org\/10.1038\/s41440-021-00771-6","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,8]]},"assertion":[{"value":"28 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"K Kario reports scholarships from Otsuka Pharmaceuticals, Daiichi Sankyo, Sumitomo Dainippon Pharma, Boehringer Ingelheim Japan\u00a0and Takeda Pharmaceuticals; honoraria from Sanwa Kagaku,\u00a0Daiichi Sankyo, Novartis Pharma,\u00a0Boehringer Ingelheim Japan and Mylan EPD outside the submitted work. The remaining authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}